NCT06009874Recruiting
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 11 Aug 2023
- Start date
- 20 Dec 2023
- Primary completion date
- Oct 2027
- Lead sponsor
- Mohammad Hussien Tantawy Soliman
- Diseases
- Coronary artery disease
- NCT number
- NCT06009874
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 20 Dec 2023 to the primary completion date, Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous coronary artery bypass surgery.
- Patients currently on or have received any SGLT-2 inhibitors.
Other illness
- History of diabetic ketoacidosis.
- Genital and urinary infections.
- History of AMI.
- Stent thrombosis.
- Severe hepatic insufficiency.
- Advanced cancer patients.
- Known allergy to SGLT-2 inhibitors.
Other
- Cardiogenic shock.
- Hypoglycemia.
- Blood pH \< 7.32.
- Hemodynamic instability.
- Females of childbearing potential without adequate contraceptive methods.
Who the study is looking for
- Patients with ST-elevation myocardial infarction (STEMI).
- STEMI was defined according to the Fourth Universal Definition of AMI.
- 18 - 80 years of age.
- Diabetics or non-diabetics.
- eGFR \> 45 ml/min/1.73m2.
- Blood pressure before first drug dosing \>110/70 mmHg.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mohammad Soliman Coordinator of this site? Confirm its status | Shibīn al Kawm | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.